Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Posters

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Clinical evaluation of extended depth of focus IOL

Poster Details

First Author: B.Febrer Bowen GERMANY

Co Author(s):    A. Spanfellner   J. Heymanns   F. Knappe              

Abstract Details

Purpose:

The aim of this study was to evaluate visual outcome, occurrence of photopic phenomena and patient satisfaction after implantation of a new IOL with extended range of vision.

Setting:

Berlin Kreuzberg and Tempelhof Eye Center, Berlin

Methods:

At two postoperative periods of time (1 month, 6 months) the monocular and binocular uncorrected dis-tance visual acuity (UDVA), the uncorrected near visual acuity (UNVA), the uncorrected intermediate visual acuity (UIVA) and the corrected distance visual acuity (CDVA) were measured. The occurrence of photopic phenomena as well as spectacle independence and patient satisfaction were recorded.

Results:

This retrospective study comprises 28 eyes of 14 Patients. At one month postoperative the mean monoc-ular UDVA was 0,14 logMAR ± 0,13 and 0,11 logMAR ± 0,08 six months postoperative. The mean monocu-lar UIVA was 0,00 logMAR ± 0,12 at one month and 0,02 logMAR ± 0,14 at the second follow up examina-tion. UNVA was 0,18 logMAR ± 0,15 at the first follow up. There is a high level of patient satisfaction alt-hough the occurrence of halos and glare is moderate.

Conclusions:

Our results confirm that the use of this new IOL may be a suitable option in the multifocal field. It pro-vides very good quality of vision at all three distances. This was also supported by high subjective patient satisfaction. However, the occurrence of halos and glare can not be denied, although it presents in an acceptable range.

Financial Disclosure:

NONE

Back to Poster listing